Logo

Henlius Announces the Acceptance of NDA Application by NMPA for Hansizhuang to Treat Esophageal cancer

Share this
Henlius

Henlius Announces the Acceptance of NDA Application by NMPA for Hansizhuang to Treat Esophageal cancer

Shots:

  • The NDA was based on the results of P-III (ASTRUM-007) evaluating Hansizhuang + CT (cisplatin + 5-FU) vs PBO + CT as 1L treatment of locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
  • The result of the study demonstrated significantly extended median PFS (5.8 vs. 5.3 mos.) and improved median OS (15.3 vs. 11.8 mos.), these findings met pre-defined efficacy criteria with favorable safety profiles and the absence of any new safety concerns
  • Hansizhuang (serplulimab), an anti-PD-1 mAb developed by Henlius, has received approval from the NMPA for treating microsatellite instability-high (MSI-H).

Ref: Henlius | Image: Henlius

Related News:- Henlius Expands its Collaboration with Accord Healthcare to Launch Hansizhuang (serplulimab injection) in Europe and India for Various Indications

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions